NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
Jazz committed $820 million at signing for an epilepsy drug with one early trial behind it. The justification is a regulatory pathway, not the data.
Month: August 2026
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC
Findings Science read / Oncology / AI & ML ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma · 18 August 2026 · 3 min read · Synopulse A Hong Kong Polytechnic University team reports that a network fusing whole slide pathology images with gene expression data reached 82.55% discrimination in classifying which … Read more
Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.
The sharpest advice in the roadmap is about vocabulary. Payers will not fund wellness, and in women’s health that classification is partly a choice.
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
One Missed, One Published the Arm That Failed, One Disclosed a Verb
Three Phase 3 toplines in one day, and the detail released runs inversely to the strength of the result. One company disclosed no number at all.
DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week
Jazz paid $820 million for a Phase 1b asset. PTC paid $111 million for a filed one. The difference was not clinical risk, it was seller leverage.
Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make
Until this summer every approved ADC held its indication alone. Two TROP2 conjugates now share one first-line population, and payers finally have a comparator.
CMS Projects: Fewer Losses and Bigger Savings. That Only Works If the Sick Are Removed.
CMS forecasts fewer disenrollments than CBO and higher savings. Both hold only if the people removed are the expensive ones, which means the sick.
Two Dominican High-Cost Lists Overlap by Only 44 Products. FOMAC Would Be a Third.
The country already covers this. Two schemes list 120 and 115 high-cost medicines, overlapping by 44. FOMAC would be a third list, starting at 13.
The Effect Size Is 0.81. The Number That Decides the Business Is 6.4 Hours.
Effect size 0.81 settles the efficacy question. The number that decides the business is 6.4 hours of supervised monitoring per dose.